NASAL POLYPS TREATMENT MARKET ANALYSIS

Nasal Polyps Treatment Market, by Drug Class, (Corticosteroids, (Nasal corticosteroids, Fluticasone, Budesonide, Mometasone, Triamcinolone, Others - Beclomethasone, Ciclesonide, etc.), Oral/Injectable Corticosteroids (Prednisone, Combination), Antibiotics, Antihistamines, Interleukin Inhibitors, (Dupilumab, Others (IL 10, IL 25 etc.)), Monoclonal Antibodies, (Mepolizumab, Omalizumab, Others), Others (Aspirin, anticholinergic agent and etc.)), by Route of Administration (Nasal, Oral, Parenteral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Aug 2022
Code : CMI2775
Pages :520
Formats :
Excel and PDF
Industry : Pharmaceutical

Regional Analysis

Global Nasal Polyps Treatment Market – Regional Analysis

On the basis of region, the global nasal polyps treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa

Among regions, North America nasal polyps treatment market is expected to hold a dominant position during the forecast period, owing to increasing chronic rhinosinusitis patients. For instance, according to 2020 data published by National Center for Biotechnology Information Chronic rhinosinusitis affected about 2% to 16% of the U.S. population. About 25 to 30% of patient were suffering from chronic rhinosinusitis with nasal polyps. Such increasing occurrence of patients may increase demand for treatment of nasal polyps, which is expected to push the nasal polyps treatment market growth.

Furthermore, Europe is also estimated to witness significant growth in the global nasal polyps treatment market, owing to increasing research and development of new drugs by market players, for the treatment of nasal polyps. For instance, in June 2019, Roche Holding AG, a pharmaceutical company, had successfully completed and announced the positive result from two Phase III multicenter studies evaluating Xolair for the treatment of adults with chronic rhinosinusitis with nasal polyps. Xolair is an injectable medicine intended to target and block immunoglobulin E.

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC, Israel, and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa